Cargando…

Genetics provides new individualized therapeutic targets for Parkinson’s disease

Detalles Bibliográficos
Autores principales:	Garcia, Eric Joshua, Sidransky, Ellen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178788/ https://www.ncbi.nlm.nih.gov/pubmed/33229749 http://dx.doi.org/10.4103/1673-5374.297076

Ejemplares similares

Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
por: McMahon, Benjamin, et al.
Publicado: (2016)

Gut microbiota: a potential therapeutic target for Parkinson’s disease
por: Baizabal-Carvallo, José Fidel
Publicado: (2020)

Emerging non-invasive therapeutic approaches targeting hypocholinergic neural systems in Parkinson’s disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2022)

Sigma-1 receptor: a potential new target for Parkinson's disease?
por: Francardo, Veronica
Publicado: (2014)

Emerging small-molecule therapeutic approaches for Alzheimer's disease and Parkinson's disease based on targeting microRNAs
por: Abdelrahman, Somaya A., et al.
Publicado: (2021)

Genetic Analysis of Pathways to Parkinson Disease
por: Hardy, John
Publicado: (2010)

Technological advances expand our knowledge of lysosomal dysfunction in neurodegeneration
por: Chen, Chase, et al.
Publicado: (2022)

SLP-2: a potential new target for improving mitochondrial function in Parkinson's disease
por: Zanon, Alessandra, et al.
Publicado: (2017)

Polyallelic structural variants can provide accurate, highly informative genetic markers focused on diagnosis and therapeutic targets: Accuracy vs. Precision
por: Roses, AD
Publicado: (2015)

Targeting chaperone-mediated autophagy for Parkinson’s disease therapy
por: Wang, Yi-Ting, et al.
Publicado: (2023)

The presence of functional blood vessels in the ischemic core provides a therapeutic target for stroke recovery
por: Morris, Gary P., et al.
Publicado: (2023)

LIM kinases in synaptic plasticity and their potential as therapeutic targets
por: Halász, Éva, et al.
Publicado: (2020)

New perspectives in iron chelation therapy for the treatment of Parkinson’s disease
por: Nuñez, Marco T., et al.
Publicado: (2019)

Gene therapy in Parkinson's disease: targeting the endplasmic reticulum proteostasis network
por: Castillo, Valentina, et al.
Publicado: (2015)

Targeting transcriptional regulators to regenerate midbrain dopaminergic axons in Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2017)

Limited therapeutic potential of astrocyte elevated gene-1 transduction in an animal model of Parkinson's disease
por: Leem, Eunju, et al.
Publicado: (2020)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Autophagy inhibition: a new therapeutic target in spinal muscular atrophy
por: Piras, Antonio, et al.
Publicado: (2018)

Longitudinal evaluation of olfactory function in individuals with Gaucher disease and GBA1 mutation carriers with and without Parkinson's disease
por: Lopez, Grisel J., et al.
Publicado: (2022)

Cancer Stem Cells Therapeutic Target Database: The First Comprehensive Database for Therapeutic Targets of Cancer Stem Cells
por: Hu, Xiaoqing, et al.
Publicado: (2016)

The innate immune system in Parkinson's disease: a novel target promoting endogenous neuroregeneration
por: Schlachetzki, Johannes CM, et al.
Publicado: (2015)

New unexpected role for Wolfram Syndrome protein WFS1: a novel therapeutic target for Alzheimer’s disease?
por: Chen, Shuo, et al.
Publicado: (2022)

Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets
por: Lorente-Gea, Laura, et al.
Publicado: (2017)

TREM2 as an evolving therapeutic target in Alzheimer’s disease
por: George, Jacob
Publicado: (2023)

Inhibition of microglial activation and induction of neurotrophic factors by flavonoids: a potential therapeutic strategy against Parkinson's disease
por: Kim, Sang Ryong
Publicado: (2015)

Interleukin 4-induced neuroprotection and regulation of microglia activation as a therapeutic approach in the MPTP model of Parkinson's disease
por: Spittau, Björn
Publicado: (2017)

Glucocerebrosidase and its relevance to Parkinson disease
por: Do, Jenny, et al.
Publicado: (2019)

Microglial metabolic reconfiguration provides a new strategy for the treatment of Alzheimer’s disease
por: Leng, Lige, et al.
Publicado: (2023)

Dorsal root ganglion – a potential new therapeutic target for neuropathic pain
por: Sapunar, Damir, et al.
Publicado: (2012)

Lymphoma stem cells: A step toward a new therapeutic target
por: Kim, Seok Jin
Publicado: (2011)

Synthetic cell pathobiology to study neurodegeneration: defining new therapeutic targets in astroglia
por: Stenovec, Matjaž, et al.
Publicado: (2016)

The Wnt/β-catenin signaling: a multifunctional target for neuroprotective and regenerative strategies in Parkinson’s disease
por: Serafino, Annalucia, et al.
Publicado: (2022)

Cell Therapies for Parkinson's Disease
por: Irion, Stefan
Publicado: (2019)

Mitochondria in the context of Parkinson's disease
por: Villacé, Patricia, et al.
Publicado: (2017)

Falling upward with Parkinson’s disease
por: Buetow, Stephen A., et al.
Publicado: (2017)

Microparticles as Novel Biomarkers and Therapeutic Targets in Coronary Heart Disease
por: Zhou, Bo-Da, et al.
Publicado: (2015)

Free ubiquitin: a novel therapeutic target for neurodegenerative diseases
por: Park, Chul-Woo, et al.
Publicado: (2021)

Immune-mediated inflammatory disease therapeutics: past, present and future
por: McInnes, Iain B., et al.
Publicado: (2021)

OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets
por: Wong, David C. S., et al.
Publicado: (2023)

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
por: Sulzer, David, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g85aqldgblh4d74veu0algjo92